论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Su M, Qin B, Liu F, Chen Y, Zhang R
Received 24 April 2017
Accepted for publication 15 September 2017
Published 23 November 2017 Volume 2017:11 Pages 3333—3341
DOI https://doi.org/10.2147/DDDT.S140354
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Frank Boeckler
Abstract: Colorectal cancer (CRC) is the third most common malignant
neoplasm worldwide. 5-Fluorouracil (5-Fu) is the most important
chemotherapeutic drug used for the treatment of CRC. However, resistance to
5-Fu therapies is a growing concern in CRC clinical practice recently.
Andrographolide (Andro) is a main bioactive constituent of the herb Andrographis paniculata , which has
various biological effects including anti-inflammation and antitumor
activities. In the present study, we investigated the effects of combined Andro
with 5-Fu against CRC HCT-116 cells. In vitro studies showed that Andro
synergistically enhanced the anti-proliferation effect of 5-Fu on HCT-116 cells
due to increased apoptotic cells. Meanwhile, results of the enzyme linked
immunosorbent assay indicated that the level of phosphorylated
cellular-mesenchymal to epithelial transition factor (p-MET) was decreased by
the combination treatment. Further study suggested that Andro promoted the
antitumor effect of 5-Fu by downregulating the level of p-MET. In conclusion,
these results confirmed the synergistic antitumor activity of Andro on CRC and
provide evidence for possible clinical application of Andro for enhancing the
antitumor effect of 5-Fu in CRC treatment.
Keywords: Andro, 5-Fu,
HCT-116 cells, apoptosis, p-MET